SiteOne Therapeutics is a clinical-stage biopharmaceutical company that develops and produces therapeutics for treating hypersensitivity disorders such as chronic cough, itch and pain. Its drug candidates are exquisitely selective inhibitors of voltage-gated sodium ion channels that are under investigation for the treatment of multiple neurogenic diseases by systemic and local routes of administration.
SiteOne Therapeutics develops novel pain therapeutics that are meant to provide treatment for acute and chronic pain. It's drugs deliver treatment to neuropathic pain via novel pain therapeutics without showing the limitations of existing drugs, such as opioids, and it enables healthcare professionals to provide an effective treatment to their patients and enhance efficiency in healthcare delivery.
SiteOne is creating a new class of non-opioid treatments that selectively interrupts electrical signals from hyperexcitable, peripheral sensory nerves before engaging the central nervous system.